Colchicine prescriptions and tolerance according to CKD stage (n=62)
| CKD stage G4 (eGFR 15–30 mL/min) | 39 (62.9%) |
| Loading dose 1 mg first day, then 0.5 mg/day, n (%) | 5/39 (12.8%) |
| Any side effect | 1 (20%) |
| 1 mg/day, n (%) | 6/39 (15.4%) |
| Any side effect | 3/6 (50%) |
| ≤ 0.5 mg/day, n (%) | 28/39 (71.8%) |
| Any side effect | 8/28 (28.6%) |
| CKD stage G5 (eGFR<15 mL/min) | 9 (14.5%) |
| Loading dose 1 mg first day, then 0.5 mg/day, n (%) | 1/9 (11.1%) |
| Any side effect | 0 |
| 1 mg/day, n (%) | 0 |
| Any side effect | 0 |
| ≤ 0.5 mg/day, n (%) | 8/9 (88.9%) |
| Any side effect | 1/8 (12.5%) |
| Patients on dialysis | 14 (22.6%) |
| Loading dose 1 mg first day, then 0.5 mg/day, n (%) | 3/14 (21.4%) |
| Any side effect | 0 |
| 1 mg/day, n (%) | 0 |
| Any side effect | 0 |
| ≤ 0.5 mg/day, n (%) | 11/14 (78,6%) |
| Any side effect | 4/11 (36.4%) |
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate.